A syndicate of investors led by Sunstone Life Science Ventures has awarded €10 million to Resalis Therapeutics Srl of Italy to advance a non-coding RNA-based compound into the clinic for obesity. The goal is to develop a treatment that could be combined with currently approved glucagon-like peptide 1 (GLP-1) medicines and achieve weight reduction that is longer lasting than at present, while preserving muscle mass. In connection with the financing, Claus Andersson, general partner of Sunstone, will join the Resalis Board of Directors.
